DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients (NCT06388122)

🧪 Interventions in This Study

• Biospecimen Collection (PROCEDURE)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Mayo Clinic in Florida — Jacksonville, Florida

📞 Contact the Study Coordinator

Phone: (855) 776-0015

Email: mayocliniccancerstudies@mayo.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in HER2-negative Breast Cancer

• CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer — Chicago, Illinois
• A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer — Bay City, Michigan
• Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer — San Francisco, California
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) — Bethesda, Maryland

Explore by condition: All HER2-negative Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.